The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Resistance to antifungals that target CYP51
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem
Pfaller, M. A., & Diekema, D. J. (2007) · Clinical Microbiology Reviews · doi:10.1128/cmr.00029-06 · Cited by 4,174 · cited 1×
“The increasing emergence of azole resistance in yeast and fungi can be attributed to the prophylactic use of azole drugs and prolonged treatment regimens in the clinic and usage of agricultural azole fungicides in crop protection [58–63].”
BackgroundHorn, D. L., Neofytos, D., Anaissie, E. J., Fishman, J. A., Steinbach, W. J., Olyaei, A. J., Marr, K. A., Pfaller, M. A., Chang, C., & Webster, K. M. (2009) · Clinical Infectious Diseases · doi:10.1086/599039 · Cited by 956 · cited 1×
“Predisposing factors for invasive candidiasis include immunosuppressive and cytotoxic therapies, treatment with broadspectrum antibiotics, HIV-AIDS or diabetes and in situ central venous catheters and urinary tract catheters [71–73].”
BackgroundEfficacy and safety of voriconazole in the treatment of acute invasive aspergillosis
Denning, D. W., Ribaud, P., Milpied, N., Caillot, D., Herbrecht, R., Thiel, E., Haas, A., Ruhnke, M., & Lode, H. (2002) · Clinical Infectious Diseases · doi:10.1086/324620 · Cited by 844 · cited 1×
“They are now used to combat fluconazoleresistant strains and species [42] and have proved especially to be effective against Aspergillus fumigatus [43, 44].”
BackgroundSanglard, D., Kuchler, K., Ischer, F., Pagani, J. L., Monod, M., & Bille, J. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.11.2378 · Cited by 815 · cited 1×
“These include mutations that alter the amino acid sequence of CYP51 [76–78], overexpression of efflux transporters (CaCDR1, CaCDR2 and CaMDR1) [79, 80], overexpression of CYP51 and alterations in the ergosterol biosynthetic pathway such asmutations inERG3.”
BackgroundNeofytos, D., Horn, D., Anaissie, E., Steinbach, W., Olyaei, A., Fishman, J., Pfaller, M., Chang, C., Webster, K., & Marr, K. (2009) · Clinical Infectious Diseases · doi:10.1086/595846 · Cited by 801
Denning, D. W., Pleuvry, A., & Cole, D. C. (2013) · Medical Mycology · doi:10.3109/13693786.2012.738312 · Cited by 495 · cited 2×
“2 million cases following tuberculosis [11–13].”
BackgroundMellado, E., Garcia-Effron, G., Alcázar-Fuoli, L., Melchers, W. J. G., Verweij, P. E., Cuenca-Estrella, M., & Rodríguez-Tudela, J. L. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01092-06 · Cited by 490 · cited 3×
“fumigatus through gene replacement experiments (though L98H also required a modified promoter sequence) [108, 111, 117–121].”
BackgroundSionov, E., Lee, H., Chang, Y. C., & Kwon-Chung, K. J. (2010) · PLoS Pathogens · doi:10.1371/journal.ppat.1000848 · Cited by 479 · cited 1×
“neoformans, promoting increased expression levels of these two proteins [139].”
BackgroundPerea, S., López-Ribot, J. L., Kirkpatrick, W. R., McAtee, R. K., Santillán, R. A., Martı́nez, M., Calabrese, D., Sanglard, D., & Patterson, T. F. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.10.2676-2684.2001 · Cited by 470
Underlying conditions in chronic pulmonary aspergillosis including simple aspergilloma
Smith, N. L., & Denning, D. W. (2011) · European Respiratory Journal · doi:10.1183/09031936.00054810 · Cited by 449
Possible Environmental Origin of Resistance of Aspergillus fumigatus to Medical Triazoles
Snelders, E., Huis in 't Veld, R. A. G., Rijs, A. J. M. M., Kema, G. H. J., Melchers, W. J. G., & Verweij, P. E. (2009) · Applied and Environmental Microbiology · doi:10.1128/aem.00231-09 · Cited by 423
Global burden of chronic pulmonary aspergillosis as a sequel to pulmonary tuberculosis
Denning, D., Pleuvry, A., & Cole, D. (2011) · Bulletin of the World Health Organization · doi:10.2471/blt.11.089441 · Cited by 420 · cited 1×
“2 million cases following tuberculosis [11–13].”
Marichal, P., Koymans, L., Willemsens, S., Bellens, D., Verhasselt, P., Luyten, W., Borgers, M., Ramaekers, F. C. S., Odds, F. C., & Vanden Bossche, H. (1999) · Microbiology · doi:10.1099/00221287-145-10-2701 · Cited by 382 · cited 2×
“Most of these substitutions cluster into three ‘hotspots’ [87] located within amino acid residues 105-165, 266-287 and 405-488.”
BackgroundEpidemiology of invasive candidiasis
Arendrup, M. C. (2010) · Current Opinion in Critical Care · doi:10.1097/mcc.0b013e32833e84d2 · Cited by 376
Determinants of Disease Presentation and Outcome during Cryptococcosis: The CryptoA/D Study
Dromer, F., Mathoulin-Pélissier, S., Launay, O., Lortholary, O., & the French Cryptococcosis Study Group (2007) · PLoS Medicine · doi:10.1371/journal.pmed.0040021 · Cited by 374
van der Linden, J. W. M., Camps, S. M. T., Kampinga, G. A., Arends, J. P. A., Debets-Ossenkopp, Y. J., Haas, P. J. A., Rijnders, B. J. A., Kuijper, E. J., van Tiel, F. H., Varga, J., et al. (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cit320 · Cited by 342
Franz, R., Kelly, S. L., Lamb, D. C., Kelly, D. E., Ruhnke, M., & Morschhäuser, J. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.12.3065 · Cited by 339
Self-citationPfaller, M. A., Diekema, D. J., Jones, R. N., Messer, S. A., & Hollis, R. J. (2002) · Journal of Clinical Microbiology · doi:10.1128/jcm.40.3.852-856.2002 · Cited by 331
Genotypic Evolution of Azole Resistance Mechanisms in Sequential Candida albicans Isolates
Coste, A., Selmecki, A., Forche, A., Diogo, D., Bougnoux, M.-E., d'Enfert, C., Berman, J., & Sanglard, D. (2007) · Eukaryotic Cell · doi:10.1128/ec.00151-07 · Cited by 305
Fungal echinocandin resistance
Walker, L. A., Gow, N. A. R., & Munro, C. A. (2010) · Fungal Genetics and Biology · doi:10.1016/j.fgb.2009.09.003 · Cited by 267
Essential Gene Identification and Drug Target Prioritization in Aspergillus fumigatus
Hu, W., Sillaots, S., Lemieux, S., Davison, J., Kauffman, S., Breton, A., Linteau, A., Xin, C., Bowman, J., Becker, J., et al. (2007) · PLoS Pathogens · doi:10.1371/journal.ppat.0030024 · Cited by 237 · cited 1×
“A conditional mutant study indicated that in the absence of both CYP51A and CYP51B, growth was abolished but not when performed individually [106].”
BackgroundMellado, E., Garcia-Effron, G., Alcazar-Fuoli, L., Cuenca-Estrella, M., & Rodriguez-Tudela, J. L. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.7.2747-2750.2004 · Cited by 210
Slaven, J. W., Anderson, M. J., Sanglard, D., Dixon, G. K., Bille, J., Roberts, I. S., & Denning, D. W. (2002) · Fungal Genetics and Biology · doi:10.1016/s1087-1845(02)00016-6 · Cited by 202 · cited 1×
“Other azole resistance mechanisms such as overexpression of CYP51 isoforms A [96, 108, 109] and B [110], point mutations in CYP51B [111, 112] and the induction and overexpression of the drug transporters atrF, AfuMDR3, AfuMDR4 and Cdr1B [109, 113–115] have been described.”
BackgroundWatson, P. F., Rose, M. E., Ellis, S. W., England, H., & Kelly, S. L. (1989) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(89)91792-0 · Cited by 197
Self-citationIdentification and Characterization of Four Azole-Resistant erg3 Mutants of Candida albicans
Martel, C. M., Parker, J. E., Bader, O., Weig, M., Gross, U., Warrilow, A. G. S., Rolley, N., Kelly, D. E., & Kelly, S. L. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00348-10 · Cited by 168
Self-citationRodero, L., Mellado, E., Rodriguez, A. C., Salve, A., Guelfand, L., Cahn, P., Cuenca-Estrella, M., Davel, G., & Rodriguez-Tudela, J. L. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.11.3653-3656.2003 · Cited by 139 · cited 1×
“The CYP51 G468S mutation [137] confers resistance to fluconazole, whilst the Y145F mutation (equivalent to Y132F in C.”
BackgroundKelly, S. L., Lamb, D. C., Loeffler, J., Einsele, H., & Kelly, D. E. (1999) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1999.1136 · Cited by 116 · cited 1×
“In addition, several mutations were expressed in Saccharomyces cerevisiae, and the isolated membrane fractions (G464S [92] and R467K [93]) and purified enzyme (T315A) were used to study azole resistance [94].”
MethodSelf-citationAzole Binding Properties of Candida albicans Sterol 14-α Demethylase (CaCYP51)
Warrilow, A. G. S., Martel, C. M., Parker, J. E., Melo, N., Lamb, D. C., Nes, W. D., Kelly, D. E., & Kelly, S. L. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00587-10 · Cited by 112 · cited 4×
“In contrast, I471T had nearly a 3fold lower Ks value than the wild-type enzyme, and this did result in more than 2-fold increase in reaction velocity [90, 91].”
BackgroundInfluentialSelf-citationDeterminants of mortality in non-neutropenic ICU patients with candidaemia.
Marriott, D. J., Playford, E. G., Chen, S., Slavin, M., Nguyen, Q., Ellis, D., Sorrell, T. C., & Study, T. A. C. (2009) · Critical Care · doi:10.1186/cc7964 · Cited by 93
Warrilow, A. G. S., Melo, N., Martel, C. M., Parker, J. E., Nes, W. D., Kelly, S. L., & Kelly, D. E. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00316-10 · Cited by 85
Self-citationKrishnan Natesan, S., Wu, W., Cutright, J. L., & Chandrasekar, P. H. (2012) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2012.06.030 · Cited by 58
Cited by
Azole fungicides – understanding resistance mechanisms in agricultural fungal pathogens
Price, C. L., Parker, J. E., Warrilow, A. G., Kelly, D. E., & Kelly, S. L. (2015) · Pest Management Science · doi:10.1002/ps.4029 · Cited by 321
Self-citationEmerging Antifungal Targets and Strategies
Ivanov, M., Ćirić, A., & Stojković, D. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23052756 · Cited by 160
“Azole binding to the active site of CYP51 is non-competitive and induces a depletion of the final biosynthetic product—ergosterol—while it also induces accumulation of 14-methylated sterols that inhibit fungal growth by reducing the integrity of the cell membrane [14].”
BackgroundLv, Q.-Z., Yan, L., & Jiang, Y.-Y. (2016) · Virulence · doi:10.1080/21505594.2016.1188236 · Cited by 133
Rybak, J. M., Ge, W., Wiederhold, N. P., Parker, J. E., Kelly, S. L., Rogers, P. D., & Fortwendel, J. R. (2019) · mBio · doi:10.1128/mbio.00437-19 · Cited by 130
Self-citationDudakova, A., Spiess, B., Tangwattanachuleeporn, M., Sasse, C., Buchheidt, D., Weig, M., Groß, U., & Bader, O. (2017) · Clinical Microbiology Reviews · doi:10.1128/cmr.00095-16 · Cited by 113
Metadata
- Authors
- Parker, J. E., Warrilow, A. G. S., Price, C. L., Mullins, J. G. L., Kelly, D. E., & Kelly, S. L.
- Venue
- Journal of Chemical Biology
- Published
- 2014-08-27
- Volume
- 7
- Issue
- 4
- Pages
- 143-161
- ISSN
- 1864-6158 (ISSN-L)
- 1864-6166
- OpenAlex
- W2142656666
- Cited by
- 204
- References
- 31
- FWCI
- 6.71
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.